Condition
Thymoma Type B3
Total Trials
3
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03134118Phase 2Active Not RecruitingPrimary
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
NCT04710628Phase 2Completed
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents
NCT02307500Phase 2Completed
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Showing all 3 trials